Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Trends in Pharmacological Sciences|September 14, 2019
Aldehyde Dehydrogenase Inhibitors for Cancer TherapeuticsSaketh S Dinavahi, Christopher G Bazewicz, Raghavendra Gowda, et al.
Cancer Research and Treatment|February 18, 2015
A Novel, Potent, Small Molecule AKT Inhibitor Exhibits Efficacy against Lung Cancer Cells In VitroSaketh S Dinavahi, Rajagopalan Prasanna, Sriram Dharmarajan, et al.
Immunology|November 3, 2018
Aldehyde dehydrogenase in regulatory T-cell development, immunity and cancerChristopher G Bazewicz, Saketh S Dinavahi, Todd D Schell, et al.
Cancer Treatment Reviews|February 13, 2020
The role of exosomes in metastasis and progression of melanomaRaghavendra Gowda, Bailey M Robertson, Soumya Iyer, et al.
Molecular Cancer Therapeutics|October 29, 2024
Emerging Role of the p53 Pathway in Modulating NK Cell-Mediated ImmunityYu-Chi Chen, Christopher G Bazewicz, Saketh S Dinavahi, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|January 11, 2018
Nanoliposomal delivery of cytosolic phospholipase A2 inhibitor arachidonyl trimethyl ketone for melanoma treatmentRaghavendra Gowda, Saketh S Dinavahi, Soumya Iyer, et al.
Molecular Pharmacology|December 16, 2017
Moving Synergistically Acting Drug Combinations to the Clinic by Comparing Sequential versus Simultaneous Drug AdministrationsSaketh S Dinavahi, Mohammad A Noory, Raghavendra Gowda, et al.
Cancer Immunology Research|April 19, 2022
Targeting WEE1/AKT Restores p53-Dependent Natural Killer-Cell Activation to Induce Immune Checkpoint Blockade Responses in "Cold" MelanomaSaketh S Dinavahi, Yu-Chi Chen, Kishore Punnath, et al.
Toxicology Letters|May 1, 2025
In silico and in vitro analysis of the genotoxic and mutagenic potential of STING modulatorsSantosh Vishwakarma, Saketh S Dinavahi, Kapil R Nikam, et al.
Cancer Letters|July 15, 2017
Improving pharmacological targeting of AKT in melanomaOmer F Kuzu, Raghavendra Gowda, Arati Sharma, et al.
Pageof 2